Neutrophil-Lymphocyte Ratio

Neutrophil-lymphocyte ratio quantitates immune system status predicting treatment response and prognosis. Elevated ratios indicate neutrophilic dominance reflecting acute inflammation. Reduced ratios suggest lymphocytic predominance. Ratio changes during treatment track immune modulation. Prognostic utility varies by disease context.

Biomarker assessment informs treatment selection. Regulatory submissions incorporate biomarker validation. Clinical outcomes correlate with ratio changes. Post-approval monitoring employs longitudinal assessment. Emerging immunological markers improve predictive value.